Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

More articles from Current Drug Therapy

  • You have access
    Omeprazole: a new drug for the treatment of acid^peptic diseases
    Gary W. Falk, MD
    Cleveland Clinic Journal of Medicine September 1991, 58 (5) 418-427;

    Gastroesophageal reflux disease, Zollinger-Ellison syndrome, duodenal ulcer, and gastric ulcer are among the disorders that have responded to treatment with this agent—the first of a new class of gastric antisecretory drugs.

  • You have access
    Treating hypertension to prevent coronary disease
    Norman M. Kaplan, MD
    Cleveland Clinic Journal of Medicine September 1991, 58 (5) 432-443;

    Past successes and failures in treating hypertension suggest ways to provide better overall therapy and reduce the incidence of coronary heart disease.

  • You have access
    Managing the hypertensive patient: reasonable goals
    Cleveland Clinic Journal of Medicine September 1991, 58 (5) 431;

    Any approach to treating hypertension should be based on multiple blood pressure readings to establish the diagnosis, aggressive nondrug therapy, and use of low doses when initiating drug therapy.

  • You have access
    Alpha- and beta-blocking agents: pharmacology and properties
    B.N.C. Prichard
    Cleveland Clinic Journal of Medicine July 1991, 58 (4) 337-350;

    Continued investigations into the multiple effects of certain alpha and beta blockers may provide clues to more effective treatment of hypertension.

  • You have access
    The continuing development of antihypertensive drugs
    Cleveland Clinic Journal of Medicine July 1991, 58 (4) 335;

    Selective alpha-1 blockers and multiple-action beta blockers hold promise for enhanced blood pressure control.

  • You have access
    Tailoring antihypertensive therapy in 1991
    Cleveland Clinic Journal of Medicine May 1991, 58 (3) 277-284;

    The trend is toward individualized treatment and away from rigid stepped care.

  • You have access
    Hypertension and the adrenergic system
    Cleveland Clinic Journal of Medicine January 1991, 58 (1) 76;

    The increasing role of adrenergic drugs may be related to the possibility that adrenergic system abnormalities contribute to the development of primary hypertension.

  • You have access
    The role of adrenergic drugs in antihypertensive therapy
    Harold D. Itskovitz, MD
    Cleveland Clinic Journal of Medicine January 1991, 58 (1) 79-93;

    The clinical effects of drugs in the adrenergic class can be predicted by the location of the alpha or beta receptors that the drug activates or inhibits.

  • You have access
    Isradipine in the treatment of hypertension: a clinical profile
    Cleveland Clinic Journal of Medicine November 1990, 57 (8) 677-684;

    A new calcium channel blocker is safe, well tolerated, and has long-term antihypertensive efficacy regardless of age or race, with no adverse effects on lipids, carbohydrate tolerance, or renal function.

  • You have access
    Understanding the actions of adrenergic receptors
    Donald G. Vidt, MD
    Cleveland Clinic Journal of Medicine July 1990, 57 (5) 480;

Pages

  • Previous
  • Next
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire